eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.
. in washington before heading to baltimore for saturday's broadcast of
.
the provider paid out on 7,469 life and 1,769 critical illness claims in the year, with men accounting for 59 per cent of life claims and 47 per cent of critical illness claims.
.
.
his heart, beating for 84 years and full of love for the woman he affectionately called his "blue-eyed guera [pronounced whedda]," felt like it was failing.
.
but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment.
.
.
.
.
.